VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Our favourite quotes of the week from around the web
7 days ago
Stay tuned for series two of the Parkinson’s Life podcast
The award-winning Parkinson’s Life podcast is back this month. Helping to amplify the voices of the international Parkinson’s community, the podcast has so far reached more than 12,000 people around the world. Thanks to the support of pharmaceutical companies, and the backing of a grant from the Boston Scientific Foundation Europe, the second series will bring together people with Parkinson’s disease and experts in their field to explore topics such as sleep hygiene, exercise and mental health, and to offer advice to listeners. Sandrine Bazile, president of the Boston Scientific Foundation Europe, says: “We fully support this project because it mirrors perfectly our mission to improve patient wellbeing using innovative solutions. We believe in the importance of the [Parkinson’s Life] podcast series, with its aim to improve the information and education available to people with Parkinson’s and their families – to help them live life to the full.”
How Parkinson’s disease could impact the way you see art
A new study from a team at the University of Pennsylvania’s Perelman School of Medicine, US, has indicated that Parkinson’s disease could affect the way people experience art. The researchers asked 43 people with the condition and 40 controls to make judgements about 10 paintings by American artist Jackson Pollock and 10 by Dutch painter Piet Mondrian, rating them according to factors including liking, beauty, motion, complexity and colour-saturation. The participants with Parkinson’s showed more of a preference for ‘high-motion’ art. They also showed a lower recognition of movement compared to controls, suggesting that the brain’s motor system may help interpret movement from static visual cues. However, the research team noted that many of the participants were on their usual medication, and that the impact of dopamine agonists on the experience of art would also need to be considered.
Neuroticism may increase risk of Parkinson’s disease, research finds
Researchers at Florida State University, US, have found that neuroticism – a personality trait that affects how people experience negative emotions – is associated with a higher risk of developing Parkinson’s disease. The scientists analysed data collected by biomedical database UK Biobank on nearly 500,000 participants aged 40 to 69. Using health records to determine the incidence of Parkinson’s disease in these participants, they found that those who scored in the top quartile of neuroticism were 80% more at risk of developing Parkinson’s than those who scored lower. Antonio Terracciano, lead researcher of the study, said: “Our findings suggest that some emotional vulnerability is present early in life, years before the development of Parkinson’s disease. It kind of gives you a better understanding of the risk factors for the disease and what could be a contributing cause […] The evidence is convincing.”